These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34866601)

  • 1. Structure of mitogen-activated protein kinase kinase 1 in the DFG-out conformation.
    Nakae S; Kitamura M; Fujiwara D; Sawa M; Shirai T; Fujii I; Tada T
    Acta Crystallogr F Struct Biol Commun; 2021 Dec; 77(Pt 12):459-464. PubMed ID: 34866601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ABC of protein kinase conformations.
    Möbitz H
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1555-66. PubMed ID: 25839999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
    Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
    J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting inactive conformations of protein kinases using active structures: conformational selection of type-II inhibitors.
    Xu M; Yu L; Wan B; Yu L; Huang Q
    PLoS One; 2011; 6(7):e22644. PubMed ID: 21818358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling conformational flexibility of kinases in inactive states.
    Schwarz D; Merget B; Deane C; Fulle S
    Proteins; 2019 Nov; 87(11):943-951. PubMed ID: 31168936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structures of the Mnk2 kinase domain reveal an inhibitory conformation and a zinc binding site.
    Jauch R; Jäkel S; Netter C; Schreiter K; Aicher B; Jäckle H; Wahl MC
    Structure; 2005 Oct; 13(10):1559-68. PubMed ID: 16216586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity reagents that target a specific inactive form of protein kinases.
    Ranjitkar P; Brock AM; Maly DJ
    Chem Biol; 2010 Feb; 17(2):195-206. PubMed ID: 20189109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
    Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
    Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases.
    Aleksandrov A; Simonson T
    J Biol Chem; 2010 Apr; 285(18):13807-15. PubMed ID: 20200154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A.
    Martin MP; Zhu JY; Lawrence HR; Pireddu R; Luo Y; Alam R; Ozcan S; Sebti SM; Lawrence NJ; Schönbrunn E
    ACS Chem Biol; 2012 Apr; 7(4):698-706. PubMed ID: 22248356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence determinants of a specific inactive protein kinase conformation.
    Hari SB; Merritt EA; Maly DJ
    Chem Biol; 2013 Jun; 20(6):806-15. PubMed ID: 23790491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type II Inhibitors Targeting CDK2.
    Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
    ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, 'DFG-out' inhibitors.
    Modi SJ; Kulkarni VM
    J Biomol Struct Dyn; 2022 Aug; 40(12):5712-5727. PubMed ID: 33459187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states.
    Lake EW; Muretta JM; Thompson AR; Rasmussen DM; Majumdar A; Faber EB; Ruff EF; Thomas DD; Levinson NM
    Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11894-E11903. PubMed ID: 30518564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?
    Zhao Z; Wu H; Wang L; Liu Y; Knapp S; Liu Q; Gray NS
    ACS Chem Biol; 2014 Jun; 9(6):1230-41. PubMed ID: 24730530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
    Zhang Q; Zhang X; You Q
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors.
    Peng YH; Shiao HY; Tu CH; Liu PM; Hsu JT; Amancha PK; Wu JS; Coumar MS; Chen CH; Wang SY; Lin WH; Sun HY; Chao YS; Lyu PC; Hsieh HP; Wu SY
    J Med Chem; 2013 May; 56(10):3889-903. PubMed ID: 23611691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors.
    Fischmann TO; Smith CK; Mayhood TW; Myers JE; Reichert P; Mannarino A; Carr D; Zhu H; Wong J; Yang RS; Le HV; Madison VS
    Biochemistry; 2009 Mar; 48(12):2661-74. PubMed ID: 19161339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Electrostatic Coupling Enables Conformational Plasticity in a Tyrosine Kinase.
    Tsai CC; Yue Z; Shen J
    J Am Chem Soc; 2019 Sep; 141(38):15092-15101. PubMed ID: 31476863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4).
    Wang L; Ferrao R; Li Q; Hatcher JM; Choi HG; Buhrlage SJ; Gray NS; Wu H
    J Biol Chem; 2019 Mar; 294(12):4511-4519. PubMed ID: 30679311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.